SUMMARY QUESTION

Is vaginal progesterone gel equivalent to vaginal micronized progesterone tablets concerning ongoing pregnancy rate and superior concerning patient convenience when used for luteal support after IVF/ICSI?

SUMMARY ANSWER

Equivalence of treatments in terms of ongoing live intrauterine pregnancy rate has not been demonstrated; the 95% confidence interval (CI) for the difference in ongoing pregnancy rate (–8.2 to 0.1%) did not lie entirely within the pre-specified equivalence interval –7 to 7%.

WHAT IS KNOWN ALREADY

No significant differences in clinical pregnancy rates have been observed between vaginal progesterone gel and other vaginal progesterone products in earlier studies. However, all previous studies included a limited number of patients.

STUDY DESIGN, SIZE AND DURATION

This was a randomized, multicentre, controlled, assessor-blinded equivalence trial in 18 fertility centres in Denmark and Sweden between March 2006 and January 2010. A web-based randomization program was used with concealed allocation of patients. Patients were randomized to one of two groups: vaginal progesterone gel or vaginal micronized progesterone tablets. There was no blinding of patients.

PARTICIPANTS AND SETTING

A total of 2057 women ≤40 years of age were included and down-regulated, using the long agonist protocol and rFSH for stimulation. Luteal support was given for 19 days after embryo transfer or until a negative pregnancy test Day 14 after embryo transfer. Patient convenience was assessed using questionnaires to be filled in 14 days after embryo transfer, before pregnancy test.

MAIN RESULTS AND THE ROLE OF CHANCE

Ongoing intrauterine pregnancy rates were 299/991 (30.2%) (95% CI 27.3–33.0%) in the progesterone gel group and 324/992 (32.7%) (29.7–35.6%) in the micronized progesterone tablet group. The difference in ongoing pregnancy rates between the groups was –4.1% (–8.2 to 0.1%) and the difference in live birth rates was –3.4% (–7.4 to 0.7%), both calculated after correction for significant confounders. Patient convenience and ease of use (1 = very convenient, 10 = very inconvenient) was in favour of progesterone gel, as the overall score was 2.9 (2.7–3.0) for progesterone gel and 4.8 (4.7–5.0; P < 0.0001) for micronized progesterone tablets. This large equivalence trial shows that, even though equality could not be demonstrated, there is no substantial difference in ongoing pregnancy rate between vaginal progesterone gel and vaginal micronized progesterone tablets. It also shows that progesterone gel is considered more convenient by the patients.

BIAS, CONFOUNDING AND OTHER REASONS FOR CAUTION

Blinding of patients was not possible in this study, but since the outcome (pregnancy) is robust, blinding would have been unlikely to affect the results. Unfortunately, owing to an error in the randomization, the intended age distribution allocated older women to the micronized progesterone tablet group. In the analysis of results, adjustments were made for age and number of embryos transferred.

GENERALIZABILITY TO OTHER POPULATIONS

The results can be generalized to other women ≥18 and ≤40 years of age undergoing IVF/ICSI who have regular menstrual cycles (25–35 days), both ovaries present and no more than two previous failed IVF attempts.

STUDY FUNDING/COMPETING INTEREST

Merck Serono supported the study but had no influence on the design of the study and was not involved in the analysis of the results or preparation of the manuscript.

TRIAL REGISTRATION NUMBER

The trial was issued with the EudraCT number 2005-001248-22 with the Protocol code number 95576471.

Source:
http://humrep.oxfordjournals.org/cgi/content/short/27/12/3467?rss=1

STUDY QUESTION

Is the endometrial mononuclear cell population in infertile patients altered in subjects with classical endometrial polyps (macropolyps) versus endometrial micropolyps that are hysteroscopically recognized as small uterine cavity protrusions?

SUMMARY ANSWER

Macropolypoid endometrium had a low density of pan-leukocytes, pan-T cells and natural killer (NK) cells, whereas micropolypoid endometrium was characterized by high density of B cells and plasmacytes, along with a low density of NK cells.

WHAT IS KNOWN ALREADY

Endometrial micropolyps co-exist at a high rate with chronic endometritis, which is an unusual plasmacyte infiltration within the endometrial stromal compartment.

STUDY DESIGN

Prospective cross-sectional study. From July 2009 to June 2011, hysteroscopy was performed for infertile women who had been suspected for endometrial macropolyps and who had repeated in vitro fertilization-embryo transfer failure over three or more cycles. Endometrial biopsy samples were obtained from the patients with macropolyps or micropolyps during the proliferative phase. Of 137 patients assessed, 30 were diagnosed with endometrial macropolyps and 34 were diagnosed with endometrial micropolyps. After the exclusion of the cases with heavy uterine bleeding, potential neoplasms, submucosal uterine fibroids, uterine septa, and/or intrauterine adhesion, 23 patients with macropolypoid endometrium; 25 patients with micropolypoid endometrium and 27 patients with non-polypoid endometrium were enrolled in the study.

Endometrial macropolyps were surgically removed, whereas chronic endometritis was treated with antibiotics. The patients were followed up until December 2011.

PARTICIPANTS/MATERIALS, SETTING, METHODS

The paraformaldehyde-fixed paraffin-embedded endometrial sections were immunostained with monoclonal antibodies against the specific markers of pan-leukocytes (CD45), pan-T cells (CD3), Th cells (CD4), Tc cells (CD8), B cells (CD20), plasmacytes (CD138), NK cells (CD56) and macrophages (CD68). The immunoreactive cells were enumerated in at least 20 non-overlapping stromal areas.

MAIN RESULTS AND THE ROLE OF CHANCE

Compared with the non-polypoid endometrium, macropolypoid endometrium contained a lower density of pan-leukocytes, pan-T cells and NK cells, whereas micropolypoid endometrium had a higher density of pan-leukocytes and B cells, along with a lower density of NK cells. Following the treatments, 10 patients with macropolypoid endometrium, 11 patients with micropolypoid endometrium and 10 patients with non-polypoid endometrium conceived.

LIMITATIONS, REASONS FOR CAUTION

One potential bias is immunohistochemical enumeration for leukocyte density was conducted by one examiner. The limitation of this study is that the results relied on endometrial biopsy specimens, of which immunological conditions may not always represent those in the whole endometrium.

WIDER IMPLICATIONS OF THE FINDINGS

There may be some ethnic or racial variances in the composition of the endometrial mononuclear cell subsets of infertile women.

STUDY FUNDING/COMPETING INTEREST(S)

This study was supported by Grand-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology (22591840). There were no conflicts of interest to declare.

Source:
http://humrep.oxfordjournals.org/cgi/content/short/27/12/3474?rss=1

STUDY QUESTION

What is the effect of natural cycle IVF in women with poor ovarian response according to the new ESHRE definition for poor ovarian responders: the Bologna criteria?

SUMMARY ANSWER

Although natural cycle IVF is a promising treatment option for normal responders, poor ovarian responders, as described by the Bologna criteria, have a very poor prognosis and do not appear to experience substantial benefits with natural cycle IVF.

WHAT IS KNOWN ALREADY

Previous trials have shown that natural cycle IVF is an effective treatment for the general infertile population and might be an option for poor ovarian responders. However, none of the trials have examined the effect of natural cycle IVF in poor responders according to the Bologna criteria, the newly introduced definition by the ESHRE Working Group on Poor Ovarian Response Definition. In this trial, we examined the effect of natural cycle IVF in poor ovarian responders fulfilling the Bologna criteria.

STUDY DESIGN, SIZE, DURATION

In this retrospective cohort trial, 164 consecutive patients, undergoing 469 natural cycle IVFs between 2008 and 2011 were included. Patients were stratified as poor and normal responders: 136 (390 cycles) were poor ovarian responders according to the Bologna criteria, whereas 28 women (79 treatment cycles) did not fulfil the criteria and were considered as normal responders.

PARTICIPANTS/MATERIALS, SETTING, METHODS

All patients were monitored with hormonal analysis and ultrasound scan every second day, from Day 7 or 8 of the cycle onwards. When a follicle of >16 mm was observed, ovulation was triggered with 5000 IU of i.m. hCG and oocyte retrieval was performed 32 h later.

MAIN RESULTS AND THE ROLE OF CHANCE

Live birth rates in poor responders according to the Bologna criteria were significantly lower compared with the control group of women; the live birth rate per cycle was 2.6 versus 8.9%, P = 0.006 and the live birth rate per treated patient was 7.4 versus 25%, P = 0.005. In poor responders according to the Bologna criteria, live birth rates were consistently low and did not differ among different age groups (≤35 years, 36–39 years and ≥40 years), with a range from 6.8 to 7.9%.

LIMITATIONS, REASONS FOR CAUTION

A limitation of our analysis is its retrospective design; however, taking into account that we included only consecutive patients treated with exactly the same protocol, the likelihood of selection bias might be considerably limited. In addition, the control group in our study refers to women of younger age and therefore the promising results among patients who did not fulfil the Bologna criteria apply only to women of younger age.

WIDER IMPLICATIONS OF THE FINDINGS

Our trial suggests that although natural cycle IVF is a promising treatment option for younger normal responders, its potential is very limited to poor ovarian responders as described by the Bologna criteria, irrespective of patient's age. This highlights the very poor prognosis of these women and therefore the urgent need for future trials to examine the effect of ovarian stimulation protocols in women with poor ovarian response as described by the Bologna criteria.

STUDY FUNDING/COMPETING INTEREST(S)

No funding was used. There are no competing interests to declare.

Source:
http://humrep.oxfordjournals.org/cgi/content/short/27/12/3481?rss=1

STUDY QUESTION

Does the presence of ultrasound diagnosed adenomyosis interfere with successful implantation in patients undergoing IVF treatment with GnRH antagonist ovarian stimulation?

SUMMARY ANSWER

The presence of ultrasound diagnosed adenomyosis was associated with a significant reduction in successful implantation of good quality embryos in patients undergoing GnRH antagonist stimulation for IVF treatment (viable clinical pregnancy rate 23.6% versus 44.6%, P= 0.017).

WHAT IS KNOWN AND WHAT THIS PAPER ADDS

There is currently no consensus regarding the impact of adenomyosis on implantation potential. Although some studies have identified alterations in the endometrial milieu in adenomyosis patients that may impact implantation, several papers have reported no associated reproductive deficit. However, these pregnancy outcome studies have primarily investigated patients undergoing long down-regulation IVF protocols, where low levels of serum estrogen (before commencing the ovarian stimulation) may inactivate the adenomyosis and potentially negate its effect on implantation. Given that the majority of fertility clinics are now moving towards the more ‘patient-friendly’ antagonist protocol, where patients are not placed in a hypo-estrogen state before commencing ovarian stimulation, the question of whether adenomyosis has an impact on IVF success rates in GnRH antagonist-stimulated IVF treatment needs to be examined.

DESIGN

This is a retrospective cohort study of 748 patients who, between April 2010 and March 2012, underwent a screening transvaginal ultrasound to identify possible pelvic pathology before commencing their IVF treatment. From this screening group, 213 patients were eligible to be included in the study as they had no obvious underlying uterine or embryonic factors that could have interfered with successful implantation (aged ≤39 years, good quality Day 4/5 embryo for single-embryo transfer, no uterine fibroids/hydrosalpinx or endometrial polyps).

PARTICIPANTS AND SETTING

There were 213 patients in a private IVF unit eligible to be included in the study, with 38 patients (17.84%) having ultrasound diagnosed adenomyosis and 175 patients having no adenomyosis on the scan. Only the first treatment cycle for each patient was included.

MAIN RESULTS AND THE ROLE OF CHANCE

The adenomyosis group had a viable clinical pregnancy rate of 23.6% compared with 44.6% in the non-adenomyosis group (P =0.017). However, the median maternal age and duration of infertility of the adenomyosis group was 2 years older and 4 months greater, respectively, than that of the non-adenomyosis group. A logistic regression analysis was performed to account for these differences between the two groups, with the adjusted results still showing a statistically significant decline in viable pregnancy rate in the adenomyosis group (OR = 0.408, CI = 0.181–0.922, P =0.031 when adjusting for maternal age; OR = 0.417, CI = 0.175–0.989, P =0.047 when adjusting for duration of infertility)

BIAS, CONFOUNDING AND OTHER REASONS FOR CAUTION

Given the retrospective nature of this study, there is risk of bias. This risk was minimized by having subjective variables such as embryo quality assessed by individuals not involved in the study, while strictly applying the pre-determined inclusion/exclusion criteria to all study participants. Furthermore, it is acknowledged that ultrasound is not a perfect test for the diagnosis of adenomyosis and, therefore, may underestimate the incidence of adenomyosis by misclassifying some patients with mild adenomyosis as not affected.

WIDER IMPLICATIONS OF THE FINDINGS

The results of this study should be representative of outcomes for any patient undergoing a GnRH antagonist ovarian stimulation cycle for IVF since standard IVF treatment protocols were used.

STUDY FUNDING/COMPETING INTEREST

MSD Australia have provided us with a small amount of funding to cover our costs (including a travel grant for Dr Thalluri to present this work at a conference).

Source:
http://humrep.oxfordjournals.org/cgi/content/short/27/12/3487?rss=1

STUDY QUESTION

Is patient screening for emotional risk factors before starting IVF treatment feasible?

SUMMARY ANSWER

Introduction of screening for emotional risk factors by a validated instrument (SCREENIVF) in couples treated by IVF or ICSI is feasible, indicated by a moderate to high and stable uptake rate, a high acceptance of the process of SCREENIVF, and a high acceptability of the presented risk profile by the patients.

WHAT IS KNOWN ALREADY

SCREENIVF is a validated screening tool to identify women at risk for emotional maladjustment preceding the start of their IVF/ICSI treatment.

STUDY DESIGN, SIZE AND DURATION

This was a prospective cohort study, including data of two cohorts of patients (304 and 342 patients), with a duration of 3 months per cohort. For the first cohort, we sent a process evaluation to 210 patients and it was completed by 91 patients.

PARTICIPANTS/MATERIALS, SETTING AND METHODS

All 304 patients (male and female) who started IVF/ICSI between 1 December 2009 and 28 February 2010 in our tertiary IVF clinic were eligible. The uptake rate of SCREENIVF was assessed as the response rate to the screening questionnaire. One year later, we re-assessed the uptake rate in 342 new patients to assess the stability of the uptake rate. A non-responder assessment in patients who did not complete SCREENIVF was carried out. Finally, patients' characteristics and their experiences with SCREENIVF as well as their consequent actions were assessed by an additional process evaluation questionnaire sent some months later to 210 patients.

MAIN RESULTS AND THE ROLE OF CHANCE

The uptake rate of SCREENIVF was 78–80%. One-third of the responders were found to be at risk for emotional maladjustment, which was comparable with previous studies using SCREENIVF. Of 27 non-responders to SCREENIVF, 41% explained non-response by ‘no actual need for psychological help’ and 19% forgot to complete the screening. The response rate to the process evaluation was 43% (n = 91). Of these, 90% found the screening was useful, and almost all patients were positive about the SCREENIVF questionnaire. Furthermore, 93% recognized themselves in the risk profile based on SCREENIVF. Of the patients at risk, 21% reported planning to seek professional help, but 46% of the at-risk patients experienced travelling distance as an obstacle to seek psychological help. We concluded that screening patients for emotional risk factors is feasible. In future, psychosocial care offered by the Internet may be promising in meeting the barrier of travelling distance.

LIMITATIONS, REASONS FOR CAUTION

People were asked to fill in SCREENIVF for clinical purposes pretreatment. There might be a selection bias in the people who did not fill in SCREENIVF, which may be due to already existing psychological problems or language problems. The low response rate of the process evaluation questionnaire and the mono-centre evaluation may be confounders and may have influenced our analysis opportunities.

WIDER IMPLICATIONS OF THE FINDINGS

The generalizability of this data is unknown with respect to other ethnic groups. Furthermore, more research is needed to evaluate psychosocial factors in male partners. Future research should also focus on the barriers and facilitators for help-seeking behaviour.

STUDY FUNDING/COMPETING INTEREST(S)

There was no funding for this study and no conflict of interest.

Source:
http://humrep.oxfordjournals.org/cgi/content/short/27/12/3493?rss=1

STUDY QUESTION

Does maternal obesity affect estrous cyclicity, embryo development and blastocyst gene expression in mice?

SUMMARY ANSWER

Maternal obesity alters estrous cyclicity and causes the down-regulation of two key metabolite receptors (Slc2a1 and Ldlr) in blastocysts recovered from diet-induced obese females, but embryo development is not affected.

WHAT IS KNOWN ALREADY

Maternal obesity reduces fertility because of effects in the periconception period, but its negative influence is on estrous cyclicity, oocyte quality or embryo development.

STUDY DESIGN, SIZE AND DURATION

This was a randomized study based on a mouse model for obesity. Twenty-one outbred NIH Swiss mice were used and obesity was induced by a diet high in fat administered for 12 weeks prior to breeding to control males.

MATERIAL, SETTING AND METHODS

Females were fed either a control diet (C, n = 9) or a diet high in fat [diet-induced obesity (DiO), n = 12] for 12 weeks, and were then co-housed with fertile males. Mice that failed to breed during 20 consecutive days were considered infertile. Control and diet-induced obese females that demonstrated vaginal plugs were euthanized 3.5 days after mating, blood was sampled for glucose and hormone measurements, corpora lutea counted and embryos recovered; the relative mRNA abundance of 11 candidate genes was determined in blastocysts by qPCR.

MAIN RESULTS AND THE ROLE OF CHANCE

Five DiO females failed to breed and displayed anovulatory ovaries (DiOI), whereas the other seven DiO females (DiOF) could breed, albeit over an extended period compared with controls. DiOF weighed significantly less than DiOI. Both groups had elevated serum insulin compared with C, although blood glucose level was only significantly higher than that in controls in the infertile DiOI group. Adiponectin was lower in the DiOI and leptin higher in both the DiOI and DiOF mice than in C. DiOF ovulated the same number of oocytes as C, and embryo development to blastocyst was normal. The expression of genes encoding metabolic hormone receptors (Insr, Igf1r, Igf2r, Adipor1, Adipor2 and Lepr) and key metabolic enzymes (Gapdh, Cpt1a and Sod2) did not differ between DiOF and C blastocysts, but that of metabolite receptors (Slc2a1 and Ldr) was down-regulated in DiOF. To limit the role of chance, the experiments were conducted in a defined laboratory setting with the proper controls, and the animals were randomly assigned to each experimental group. Moreover, a P-value of < 0.05 was chosen to determine whether the differences observed between the groups were statistically significant.

LIMITATIONS AND REASONS FOR CAUTION

The results obtained may not fully extrapolate to humans. Also, as follicular activity was not monitored while breeding, so the extended breeding period for DiOF group might be explained by behavioral abnormalities occurring in normal cycling animals.

WIDER IMPLICATIONS OF THE FINDINGS

DiO alters the estrous cycle in the mouse model and demonstrates a role of obesity in infertility. The data also suggest that in an outbred, genetically diverse population, such as the human, individual susceptibility to obesity and associated infertility induced by diet exists. The apparently normal development to blastocyst observed in fertile, obese females suggests that preimplantation embryos can resist potentially adverse outcomes caused by an oversupply of fatty acids and glucose under in vivo conditions. This metabolic plasticity may, in part, be due to an ability to down-regulate metabolite transporters, thereby preventing excessive nutrient uptake.

STUDY FUNDING/COMPETING INTEREST(S)

The research was supported by funds from the University of Missouri, grants from the National Institutes of Health and by a fellowship from the Lalor Foundation. There were no competing interests.

TRIAL REGISTRATION NUMBER

Not applicable.

Source:
http://humrep.oxfordjournals.org/cgi/content/short/27/12/3513?rss=1

Antidepressants while pregnant put mother and child at significant risk
From Boston - Antidepressants during pregnancy put the mother and child at significant risk of serious complications, according to a report published in Human Reproduction. Researchers conducted a meta-analysis of several published studies that examined the use of SSRIs during pregnancy. The antidepressants were associated with several complications, including increased risk of: -Miscarriage -Cardiac defects -Preterm birth -Low birth weight -Autism spectrum disorderFrom:insidermedicineViews:2 0ratingsTime:00:35More inScience Technology

See the original post here:
Antidepressants while pregnant put mother and child at significant risk - Video

STUDY QUESTION

Do social support and social strain from social relations have an impact on the decision to terminate fertility treatment among men and women after 1 year of unsuccessful treatment?

SUMMARY ANSWER

Several functional aspects of social relations show an impact on the probability to terminate treatment; social support from family significantly decreases the probability to terminate and experience of conflicts or problematic communication with the partner significantly increases the probability to terminate treatment.

WHAT IS KNOWN ALREADY

Fertility patients can experience psychological, physical and economical strain as consequences of infertility and fertility treatment, and previous studies have shown that these pressures increase the probability of deciding to terminate treatment before the treatment options are exhausted. Some studies have indicated that social relations can also have an effect.

STUDY DESIGN, SIZE, DURATION

This study is part of the prospective Infertility Cohort from the Copenhagen Multi-centre Psychosocial Infertility Research Programme. Baseline data were collected during January 2000–August 2001 among patients recruited at five Danish fertility clinics during their initial visit and follow-up data were collected after 1 year.

PARTICIPANTS/MATERIALS, SETTING, METHODS

The study group (n = 777; 427 women, 350 men) consisted of patients who did not achieve a live birth or an ongoing pregnancy during follow-up. Social support and strain from the patients' partner, family, family-in-law, friends and colleagues were measured at baseline and the decision to terminate treatment while treatment options were not yet exhausted was measured as the outcome at the 1-year follow-up.

MAIN RESULTS AND THE ROLE OF CHANCE

At the 1-year follow-up, 23% of the study group had decided to terminate treatment. For women, low levels of family support, specifically with regard to infertility, were associated with the termination of treatment after 1 year [odds ratio (OR) 6.1, 95% confidence interval (CI) 2.2–16.8] and, for men, low levels of general family support had a similar impact (OR 2.6, 95% CI 1.0–7.0). For men, difficulties in communicating with their partner about the infertility increased the probability of terminating the treatment (OR 2.3, 95% CI 1.2–4.1) and, for women, frequent conflicts with their partner increased the probability of terminating the treatment (OR 12.4, 95% CI 2.9–54.1). For women, conflicts with friends were also a predictor of treatment termination (OR 2.2, 95% CI 1.2–4.2).

WIDER IMPLICATIONS OF THE FINDINGS

Functional aspects of social relations have an impact on the decision to terminate fertility treatment among men and women. The findings in this study provide new insights into how the close social environment can have implications for men and women going through fertility treatment.

FUNDING

This study has received support from the Danish Health Insurance Fund (J.nr. 11/097-97), the Else and Mogens Wedell-Wedellsborgs Fund, the manager E. Danielsens and Wife's Fund, the merchant L.F. Foghts Fund, the Jacob Madsen and Wife Olga Madsen's Fund, and the Engineer K.A. Rohde and Wife's Fund. The authors have no conflicts of interest to declare.

Source:
http://humrep.oxfordjournals.org/cgi/content/short/27/12/3502?rss=1

Miracle of Reproduction - 1963
Reproduction. Shots of nature and animals, flowers, fish, chicken and cow reproductive processes in order to finally explain human reproduction. The male #39;s role in the human reproductive process is distant -- implied through the similar process that occurs among the animals. Ultimately, the joys of reproduction can be looked forward to in the bond of matrimony. Calving is shown, an illustration of a magnifying glass and arrow, labelled "EGG", illustration with arrow pointing first to a fish and then an elephant, violet, and a blue-bird, illustration of a flower, arrows labelled with "PISTIL" and "OVARY" illustration of two flowers, labelled "MOTHER" and "FATHER", with an illustration of a bee, fish eggs. the planting of seeds, fish in an aquarium.From:Bel99TVViews:0 0ratingsTime:15:13More inEducation

Read this article:
Miracle of Reproduction - 1963 - Video

Main Show Only - Endgame - Population Reduction - Coast to Coast AM
Filmmaker and activist Alex Jones discussed his film, Endgame, which chronicles the so-called "global elite #39;s" rise to power and purportedly reveals their secret plan to reduce the world #39;s population by 80%. Jones traced the origin of The Bilderberg Group and their several-decades-long pursuit of #39;negative eugenics, #39; a movement which advocated various methods (eg, abortion, forced sterilization) to control human reproduction/population. According to Jones, the elites have been working to create a world government under which a scared and submissive populace will unknowingly be victims of staged releases of bioweapons and deadly superplagues. "Despite everything they [the global elite] have been doing, they have been unable to get the numbers that they wanted [dead]," Jones said, noting that the globalists are behind schedule by at least six years. Jones also talked about Transhumanism, HG Wells, Planned Parenthood founder Margaret Sanger, and the Georgia Guidestones. View the official #39;Endgame #39; trailer, and get more info on the topic at prisonplanet.com.From:Geoff ThomasViews:0 0ratingsTime:01:16:43More inEducation

Go here to read the rest:
Main Show Only - Endgame - Population Reduction - Coast to Coast AM - Video

SSRI Antidepressants are Risky in Pregnancy
The October 31, 2012 issue of Human Reproduction published an article from Harvard and Tufts Medical Centers stating that SSRI antidepressants should not be used in pregnancy because they lead to worsened pregnancy outcomes, have not been shown to be of benefit, and are massively overused in clinical practice. This family of drugs is associated with an elevated risk for miscarriage, preterm births, neonatal health complications and possible longer term neurobehavioral abnormalities such as autism. Who in their right mind would take these drugs during pregnancy, and even worse, why would an MD prescribe them! Antidepressants are now the most commonly prescribed drug between the ages of 18 and 44, the childbearing years for most women. Sadly, 11% of women doing invitro fertilizations are prescribed these drugs and the data shows that they reduce the rate for pregnancy and for miscarriage. Treatments recommended included cognitive behavioral therapy (psychotherapy), exercise, relaxation training, yoga, acupuncture, and nutritional supplements.From:DoctorSaputoViews:0 0ratingsTime:06:16More inEducation

Read more here:
SSRI Antidepressants are Risky in Pregnancy - Video

Causes Of Infertility New Jersey Fertility Doctor Jane Miller, Md [Reasons For Infertility]
click here to learn more==)) yupurl.com Center for Human Reproduction is a world renowned IVF, infertility, fertility, egg donation and gender selection center in New York, NY. We #39;re located next to Women and Infants Hospital in Providence, Rhode Island with easy access from Route 95 and 195. Frequently asked questions; Responsible sourcing; Ericsson RSS Feeds; Commenting Rules; Local Sites; Related sites . Male factor infertility. Success stories success rates. Endocrinology services. Frequently asked questions. Find a doctor. Patient forms. Smoking and Infertility; Weight and Infertility ; Causes of Infertility; Take our Free Fertility Check if you #39;re trying to get pregnant! We welcome the opportunity to provide a variety of fertility services to you, and would be happy to assist you with any of your fertility concerns. Fertility Treatment Discounts. As well, during the economic down-turn, CHR will extend IVF and fertility treatments discounts to qualifying individuals and families.From:fatfatloseViews:0 0ratingsTime:05:26More inEntertainment

More here:
Causes Of Infertility New Jersey Fertility Doctor Jane Miller, Md [Reasons For Infertility] - Video

Causes Of Male Infertility -- Los Angeles Fertility Doctors [Reasons For Infertility]
click here to learn more==)) yupurl.com Center for Human Reproduction is a world renowned IVF, infertility, fertility, egg donation and gender selection center in New York, NY. We #39;re located next to Women and Infants Hospital in Providence, Rhode Island with easy access from Route 95 and 195. Frequently asked questions; Responsible sourcing; Ericsson RSS Feeds; Commenting Rules; Local Sites; Related sites . Male factor infertility. Success stories success rates. Endocrinology services. Frequently asked questions. Find a doctor. Patient forms. Smoking and Infertility; Weight and Infertility ; Causes of Infertility; Take our Free Fertility Check if you #39;re trying to get pregnant! I think of old May Day traditions, girls dancing around its trunk with blossom falling, ties to fertility, love and happiness. Liz Chiu. More favourite trees. Fertility Treatment Discounts. As well, during the economic down-turn, CHR will extend IVF and fertility treatments discounts to qualifying individuals and families.From:fatfatloseViews:0 0ratingsTime:00:27More inEntertainment

See original here:
Causes Of Male Infertility -- Los Angeles Fertility Doctors [Reasons For Infertility] - Video

Watch Mickey Coffler, Md - What Are Some Causes Of Infertility In Men? - Reasons For Infertility
click here to learn more==)) yupurl.com Center for Human Reproduction is a world renowned IVF, infertility, fertility, egg donation and gender selection center in New York, NY. We #39;re located next to Women and Infants Hospital in Providence, Rhode Island with easy access from Route 95 and 195. Frequently asked questions; Responsible sourcing; Ericsson RSS Feeds; Commenting Rules; Local Sites; Related sites . Male factor infertility. Success stories success rates. Endocrinology services. Frequently asked questions. Find a doctor. Patient forms. Smoking and Infertility; Weight and Infertility ; Causes of Infertility; Take our Free Fertility Check if you #39;re trying to get pregnant! I think of old May Day traditions, girls dancing around its trunk with blossom falling, ties to fertility, love and happiness. Liz Chiu. More favourite trees. Fertility Treatment Discounts. As well, during the economic down-turn, CHR will extend IVF and fertility treatments discounts to qualifying individuals and families.From:onlinetherapistusViews:0 0ratingsTime:04:18More inEntertainment

Read the original post:
Watch Mickey Coffler, Md - What Are Some Causes Of Infertility In Men? - Reasons For Infertility - Video

Watch How To Get Pregnant? - To Conceive
click here to learn more==)) yupurl.com in-vitro-fertilization. Hail, O favored one, the Lord is with you!.. And behold, you will conceive in your womb and bear a son, and you shall call his name Jesus." - Luke 1:26-32. Miten asennan palovaroittimen? Toimiva palovaroitin haistelee ilmaa jatkuvasti ja havaitsee savun nopeasti, kunhan varoitin on oikein asennettu. By : thebubblelush View : 129965. 5-6 weeks Ultrasound The doctor wasn #39;t exactly sure how far along we were, but he said 5 weeks 1 day give or take a week. World Wide Sires, Ltd. is the world #39;s leading cattle genetics marketing organization representing the majority of the US Artificial Insemination Cooperatives. Center for Human Reproduction is a world renowned IVF, infertility, fertility, egg donation and gender selection center in New York, NY. Center for Human Reproduction is a world renowned IVF, infertility, fertility, egg donation and gender selection center in New York, NY. Center for Human Reproduction is a world renowned IVF, infertility, fertility, egg donation and gender selection center in New York, NY.From:onlinetherapistusViews:0 0ratingsTime:02:52More inEntertainment

Read the original post:
Watch How To Get Pregnant? - To Conceive - Video

Watch Trying To Conceive: Cycle #1, Cycle Day 24 - To Conceive
click here to learn more==)) yupurl.com in-vitro-fertilization. Hail, O favored one, the Lord is with you!.. And behold, you will conceive in your womb and bear a son, and you shall call his name Jesus." - Luke 1:26-32. Miten asennan palovaroittimen? Toimiva palovaroitin haistelee ilmaa jatkuvasti ja havaitsee savun nopeasti, kunhan varoitin on oikein asennettu. By : thebubblelush View : 129965. 5-6 weeks Ultrasound The doctor wasn #39;t exactly sure how far along we were, but he said 5 weeks 1 day give or take a week. World Wide Sires, Ltd. is the world #39;s leading cattle genetics marketing organization representing the majority of the US Artificial Insemination Cooperatives. Center for Human Reproduction is a world renowned IVF, infertility, fertility, egg donation and gender selection center in New York, NY. Center for Human Reproduction is a world renowned IVF, infertility, fertility, egg donation and gender selection center in New York, NY. Center for Human Reproduction is a world renowned IVF, infertility, fertility, egg donation and gender selection center in New York, NY.From:fatfatloseViews:13 0ratingsTime:00:34More inEntertainment

Follow this link:
Watch Trying To Conceive: Cycle #1, Cycle Day 24 - To Conceive - Video

Epigenetics And Human Reproduction
ll4.me Epigenetics And Human Reproduction Preface B. Jegou.- Part 1 - Medical aspects and questions raised on the molecular basis of epigenome involvement in reproduction.- Part 2 - Fundamental aspects of genome and epigenome reprogramming during gametogenesis.- Part 3 Re-organization of nuclear compartments during gametogenesis.- Part 4 - Fundamental aspects of gene expression regulation during gametogenesis.- Subject index. EAN/ISBN : 9783642147739 Publisher(s): Springer, Berlin Discussed keywords: Epigenetik, Reproduktionsmedizin Format: ePub/PDF Author(s): Rousseaux, Sophie - Khochbin, Saadi Preface B. Jegou.- Part 1 - Medical aspects and questions raised on the molecular basis of epigenome involvement in reproduction.- Part 2 - Fundamental aspects of genome and epigenome reprogramming duFrom:cheryljoy9854Views:0 0ratingsTime:00:11More inPeople Blogs

Read the original:
Epigenetics And Human Reproduction - Video

Watch Pregnancy Tips : How To Become Pregnant With Twins Naturally - Becoming Pregnant
click here to learn more==)) yupurl.com Ballot boxes open in Ukraine on Sunday morning in a vote pregnant with implications for its democratic future and EU ties. Related. Adobe is changing the world through digital experiences. We help our customers create, deliver, and optimize content and applications. Also, get great tips about how to deal with those annoying pregnancy discomforts like morning sickness. Baby Care. camera phone. Trans-Video Phone Service. For over 50 years, your local, family-owned communications company! Topics covered include palpation skills, estimating fetal weight, amniotic fluid, prolapse, fetal heart tones and frank, footling and complete breech. How do I get a login? Regional Sites select Academy Locator. Find an academy near you. Useful Links. Center for Human Reproduction is a world renowned IVF, infertility, fertility, egg donation and gender selection center in New York, NY. EAW is the worldwide technological and market leader in the design and manufacture of high-performance, professional loudspeaker systems.From:fatfatloseViews:0 0ratingsTime:02:09More inEntertainment

Read the original here:
Watch Pregnancy Tips : How To Become Pregnant With Twins Naturally - Becoming Pregnant - Video

Watch How To Get Pregnant? - Becoming Pregnant
click here to learn more==)) yupurl.com Ballot boxes open in Ukraine on Sunday morning in a vote pregnant with implications for its democratic future and EU ties. Related. Adobe is changing the world through digital experiences. We help our customers create, deliver, and optimize content and applications. Also, get great tips about how to deal with those annoying pregnancy discomforts like morning sickness. Baby Care. camera phone. Trans-Video Phone Service. For over 50 years, your local, family-owned communications company! Topics covered include palpation skills, estimating fetal weight, amniotic fluid, prolapse, fetal heart tones and frank, footling and complete breech. How do I get a login? Regional Sites select Academy Locator. Find an academy near you. Useful Links. Center for Human Reproduction is a world renowned IVF, infertility, fertility, egg donation and gender selection center in New York, NY. EAW is the worldwide technological and market leader in the design and manufacture of high-performance, professional loudspeaker systems.From:fatfatloseViews:0 0ratingsTime:00:31More inEntertainment

See the original post:
Watch How To Get Pregnant? - Becoming Pregnant - Video

Pregnancy Tips - 10 Things To Know Before Becoming Pregnant [Becoming Pregnant]
click here to learn more==)) yupurl.com Ballot boxes open in Ukraine on Sunday morning in a vote pregnant with implications for its democratic future and EU ties. Related. Adobe is changing the world through digital experiences. We help our customers create, deliver, and optimize content and applications. Also, get great tips about how to deal with those annoying pregnancy discomforts like morning sickness. Baby Care. camera phone. Trans-Video Phone Service. For over 50 years, your local, family-owned communications company! Topics covered include palpation skills, estimating fetal weight, amniotic fluid, prolapse, fetal heart tones and frank, footling and complete breech. How do I get a login? Regional Sites select Academy Locator. Find an academy near you. Useful Links. Center for Human Reproduction is a world renowned IVF, infertility, fertility, egg donation and gender selection center in New York, NY. EAW is the worldwide technological and market leader in the design and manufacture of high-performance, professional loudspeaker systems.From:onlinetherapistusViews:9 0ratingsTime:05:26More inEntertainment

Link:
Pregnancy Tips - 10 Things To Know Before Becoming Pregnant [Becoming Pregnant] - Video